当前位置: 首页 >> 检索结果
581. Patient experiences and perspectives of DMARD monitoring in Australians with long-disease-duration rheumatoid arthritis and psoriatic arthritis.
作者: Morgan Witts.;Rachelle Buchbinder.;Susan Lester.;Jessica Stanhope.;Vibhasha Chand.;Claire Barrett.;Rachel J Black.;Marissa Lassere.;Lyn March.;Paul Kubler.;Catherine L Hill.;Philip C Robinson.
来源: BMC Rheumatol. 2025年9卷1期126页
Regular laboratory testing is recommended for monitoring disease activity and adverse effects in people taking conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), yet the perspectives and experiences of patients have not been examined and may inform practice. As such, we aimed to determine the experiences and perceptions of laboratory monitoring in Australian adults using csDMARDs for rheumatoid arthritis (RA) or psoriatic arthritis (PsA).
583. Vascular uptake on 18F-FDG PET/CT predicts relapse in new-onset PMR.
作者: Ningqi Dai.;Xinyi Sun.;Linzi Meng.;Jialin Teng.;Chengde Yang.;Xiaoyue Chen.;Huihui Chi.
来源: Rheumatology (Oxford). 2026年65卷1期
In this study, we utilize 18F-fluorodeoxyglucose (FDG) PET/CT to assess vascular involvement in patients with PMR, aiming to clarify its role in identifying subclinical GCA and its potential association with disease relapse.
584. Pharmacological management of spondyloarthritis associated with inflammatory bowel disease: a systematic review of efficacy, safety, and emerging therapies.
作者: Mohammed Khalil Jnyah.;Imane El Mezouar.;Nessrine Akasbi.;Taoufik Harzy.
来源: BMC Rheumatol. 2025年9卷1期125页
Spondyloarthritis (SpA) is a prevalent extraintestinal symptom of inflammatory bowel disease (IBD), impacting up to 20% of patients and considerably contributing to the disease burden. The coexistence of inflammatory bowel disease and spondyloarthritis poses therapeutic problems due to the necessity for simultaneous management of intestinal and musculoskeletal inflammation.
589. Responsiveness of spondyloarthritis-specific health utilities based on the ASAS Health Index (U-ASAS-HI): an ancillary analysis from the ASAS-HI validation study.
作者: Omar-Javier Calixto.;Xenofon Baraliakos.;Annelies Boonen.;Wilson Bautista-Molano.;Ivette Essers.;Désirée van der Heijde.;Juergen Braun.;Uta Kiltz.
来源: Rheumatology (Oxford). 2026年65卷1期
To assess responsiveness of the spondyloarthritis (SpA)-specific universal health utility from the ASAS Health Index (U-ASAS-HI) compared with generic health utilities (EQ-5D-5L and SF-6D).
590. Cancer risk in patients with rheumatoid arthritis receiving biologic and targeted synthetic disease-modifying antirheumatic drugs: results from the BIOBADASER III registry.
作者: Juan Molina-Collada.;Lucía Otero-Varela.;Paloma Vela.;Sara Manrique.;Celia Erausquin.;Cristina Campos.;Javier Manero.;Jerusalem Calvo.;Lorena Expósito.;Javier García González.;María Dolores Ruiz Montesinos.;Elena Rabadán.;Antonio Mera Varela.;Inmaculada Ros Vilamajo.;María Colazo Burlato.;Chamaida Plasencia.;Fernando Sánchez-Alonso.;Isabel Castrejón.; .
来源: Rheumatology (Oxford). 2026年65卷1期
The objective of this study was to assess the risk of cancer in patients with RA treated with biologic and targeted synthetic DMARDs (b/tsDMARDs).
591. Mechanical stress promotes synovial inflammation and osteoarthritis development via the NF-κB p52/IL-6 signalling pathway.
作者: Yi Shen.;Wei Sun.;Yu Liu.;Suxun Pan.;Huanzhong Ji.;Guangsen Zheng.;Jiashun Wu.
来源: Rheumatology (Oxford). 2026年65卷1期
TM joint OA (TMJOA) is a multifactorial degenerative disorder involving biomechanical and inflammatory processes. Yet, how mechanical stress causes synovial inflammation and cartilage degradation is unclear. This study aimed to explore the relationship between mechanical stress and inflammatory responses in TMJOA.
592. Association between grip and core muscle strength in people with axial spondyloarthritis and healthy controls.
作者: Anne-Kathrin Rausch Osthoff.;Marina Bruderer-Hofstetter.;Lea Ettlin.;Fiona Bischofberger.;Selina Papritz.;Alexandra Schwab.;Franco Weidmann.;Karin Niedermann.
来源: BMC Rheumatol. 2025年9卷1期124页
Annual fitness assessments are performed during group exercise therapy for people with axial Spondyloarthritis (axSpA) living in Switzerland. The core strength test (CST) is time-consuming, and interpretation limited. Thus, the objectives were to 1) compare the CST-performance of people with axSpA and healthy controls, and 2) evaluate if hand grip strength can be used as a proxy for core strength.
593. Relationship between anti-Epstein-Barr virus early antigen diffuse type and restricted type immunoglobulin G antibodies and disease activity and autoantibodies in rheumatoid arthritis: a retrospective observational study.
作者: Noboru Kitamura.;Yosuke Nagasawa.;Kumiko Akiya.;Hirotake Inomata.;Hideki Nakamura.
来源: BMC Rheumatol. 2025年9卷1期123页
This study examined to examine the relationship of Epstein-Barr virus (EBV) in rheumatoid arthritis (RA) by evaluating disease activity and autoantibody levels in positive and negative cases using the anti-EBV early antigen diffuse type and restricted type (EA-DR) immunoglobulin G (IgG) antibody.
594. Injury and local injection and the risk of foot/ankle osteoarthritis: a case-control study in retired UK male professional footballers.
作者: Ahmed Ali Thanoon.;Shima Espahbodi.;Monirah Ali Shuaib.;Bonnie Millar.;Ashley Duncan.;Catherine J Bowen.;Terence W O'Neill.;Richard J Wakefield.;Fiona E Watt.;David A Walsh.;Gordon Fuller.;Mark E Batt.;Sanjay M Parekh.;Gwen Sascha Fernandes.;Michael Doherty.;Weiya Zhang.
来源: Rheumatology (Oxford). 2026年65卷1期
The objective of this study was to examine whether foot/ankle injury and injection contribute to the risk of foot/ankle OA in retired UK male professional footballers.
596. Pregnancy outcomes in patients with systemic vasculitis in the USA from 2007 to 2022: an administrative claims-based study.
作者: Audra Horomanski.;Amadeia Rector.;Gary M Shaw.;Julia F Simard.
来源: Lancet Rheumatol. 2026年8卷2期e88-e97页
Systemic vasculitides are rare, heterogeneous, inflammatory disorders associated with high morbidity and mortality. Recent therapeutic advancements have improved life expectancy and reproductive opportunities for patients with vasculitis, but research on preterm delivery, maternal pregnancy complications, and medication use is limited. We aimed to investigate pregnancy outcomes in patients with systemic vasculitis using administrative claims data.
598. Anti-BCMA CAR-T for the treatment of IgG4-related disease: clinical assessment and single-cell transcriptomic analysis.
作者: Shaozhe Cai.;Yu Chen.;Cong Ye.;Umehara Hisanori.;Jishuai Zhang.;Ziwei Hu.;Wei Sun.;Lingli Dong.
来源: Lancet Rheumatol. 2025年7卷12期e834-e836页 599. Skeletal muscle effects of Janus kinase inhibition in rheumatoid arthritis (RAMUS): a single-arm, experimental medicine study.
作者: Joshua L Bennett.;Kieren G Hollingsworth.;Arthur G Pratt.;Abbie E A Degnan.;Gráinne S Gorman.;Catherine Feeney.;Najib Naamane.;Jérémie Nsengimana.;Avan A Sayer.;Amy E Anderson.;John D Isaacs.
来源: Lancet Rheumatol. 2026年8卷1期e42-e52页
Rheumatoid arthritis increases the risk of generalised muscle wasting, with chronic inflammation contributing to the loss of muscle mass and strength. Tofacitinib, a Janus kinase (JAK) inhibitor used to treat rheumatoid arthritis, increases serum creatinine concentrations without conclusive evidence of nephrotoxicity. In the Rheumatoid Arthritis and Muscle (RAMUS) study, we investigated whether tofacitinib affects muscle volume, strength, and function.
|